Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis

Company Overview

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Key Stats

• Today's Range: $131.87 to $131.87
• 50-Day Range: $126.90 to $131.92
• 52-Week Range: $64.09 to $131.98
• Volume: N/A
• Average Volume: 1.47 million shs
• Market Capitalization: $14.05 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $106.23
• Consensus Rating: Hold

Intra-Cellular Therapies Stock Analysis - MarketRank™

Intra-Cellular Therapies scored higher than 69% of companies evaluated by MarketBeat, and ranked 263rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Intra-Cellular Therapies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 5 buy ratings, 10 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Intra-Cellular Therapies has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.19 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intra-Cellular Therapies has a P/B Ratio of 21.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.58% of the float of Intra-Cellular Therapies has been sold short.

Short Interest Ratio / Days to Cover

Intra-Cellular Therapies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intra-Cellular Therapies has recently increased by 14.59%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intra-Cellular Therapies does not currently pay a dividend.

Dividend Growth

Intra-Cellular Therapies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.23

Percentage of Shares Shorted

2.58% of the float of Intra-Cellular Therapies has been sold short.

Short Interest Ratio / Days to Cover

Intra-Cellular Therapies has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Intra-Cellular Therapies has recently increased by 14.59%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.05

News Sentiment

Intra-Cellular Therapies has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Intra-Cellular Therapies this week, compared to 8 articles on an average week.

Search Interest

Only 1 people have searched for ITCI on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.

MarketBeat Follows

14 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.60% of the stock of Intra-Cellular Therapies is held by insiders.

Percentage Held by Institutions

92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ITCI Stock Analysis - Frequently Asked Questions

How have ITCI shares performed this year?

Intra-Cellular Therapies' stock was trading at $83.52 at the start of the year. Since then, ITCI stock has increased by 57.9% and is now trading at $131.87.
View the best growth stocks for 2025 here.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings data on Friday, February, 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.08. The biopharmaceutical company earned $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative trailing twelve-month return on equity of 9.93%.

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' top institutional shareholders include MassMutual Private Wealth & Trust FSB. Insiders that own company stock include Sharon Mates, Rory B Riggs, Joel S Marcus, Mark Neumann, Suresh K Durgam, Nostrand Robert L Van, Michael Halstead and Lawrence J Hineline.
View institutional ownership trends.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 2/21/2025
• Today: 4/04/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ITCI
• CIK: 1567514
• Web: www.intracellulartherapies.com
• Phone: (464) 440-9333
• Fax: 646-440-9334
• Employees: 560
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $106.23
• High Stock Price Target: $132.00
• Low Stock Price Target: $74.00
• Potential Upside/Downside: -19.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 15 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-139,670,000.00
• Net Margins: -14.07%
• Pretax Margin: -13.87%
• Return on Equity: -9.93%
• Return on Assets: -8.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.66
• Quick Ratio: 7.51

Sales & Book Value

• Annual Sales: $680.50 million
• Price / Sales: 20.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.15 per share
• Price / Book: 21.44

Miscellaneous

• Outstanding Shares: 106,522,000
• Free Float: 103,563,000
• Market Cap: $14.05 billion
• Optionable: Optionable
• Beta: 0.69